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Abstract
Background: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
(CADASIL) is a monogenic, hereditary, small vessel disease of the brain causing stroke and vascular dementia in
adults. CADASIL has previously been shown to be caused by varying mutations in the NOTCH3 gene. The disorder
is often misdiagnosed due to its significant clinical heterogeneic manifestation with familial hemiplegic migraine
and several ataxia disorders as well as the location of the currently identified causative mutations. The aim of this
study was to develop a new, comprehensive and efficient single assay strategy for complete molecular diagnosis of
NOTCH3 mutations through the use of a custom next-generation sequencing (NGS) panel for improved routine
clinical molecular diagnostic testing.
Results: Our custom NGS panel identified nine genetic variants in NOTCH3 (p.D139V, p.C183R, p.R332C, p.Y465C, p.
C597W, p.R607H, p.E813E, p.C977G and p.Y1106C). Six mutations were stereotypical CADASIL mutations leading to
an odd number of cysteine residues in one of the 34 NOTCH3 gene epidermal growth factor (EGF)-like repeats,
including three new typical cysteine mutations identified in exon 11 (p.C597W; c.1791C>G); exon 18 (p.C977G; c.
2929T>G) and exon 20 (p.Y1106C; c.3317A>G). Interestingly, a novel missense mutation in the CACNA1A gene was
also identified in one CADASIL patient. All variants identified (novel and known) were further investigated using in
silico bioinformatic analyses and confirmed through Sanger sequencing.
Conclusions: NGS provides an improved and effective methodology for the diagnosis of CADASIL. The NGS
approach reduced time and cost for comprehensive genetic diagnosis, placing genetic diagnostic testing within
reach of more patients.
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Background
The stroke syndrome CADASIL [MIM 125310] (cerebral
autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy) disorder results in neuronal
white matter abnormalities and is characterised by a variety
of symptoms including, vascular degeneration, recurrent
subcortical ischaemic strokes, progressive cognitive decline,
dementia, migraine with aura (22 % of patients) and prema-
ture death [1]. The unique deposition of granular osmiophi-
lic material (GOM) in systemic and brain vasculature
differentiates CADASIL patients from those suffering simi-
lar hereditary vascular disorders [2]. CADASIL is often mis-
diagnosed due to its significant clinically heterogeneic
manifestation with familial hemiplegic migraine and several
ataxia disorders, as these disorders have an autosomal dom-
inant mode of inheritance and share clinical characteristics
such as hemiplegic migraine, migraine with typical aura
and progressive ataxia [3–6]. Mutations implicated in
CADASIL have been identified on chromosome 19, specif-
ically within NOTCH3 (MIM 600276), which encodes a
transmembrane receptor primarily expressed in vascular
smooth muscle cells. NOTCH3 located at 19p13 is 33
exons long and spans approximately 7 kb [4]. Currently, at
least 200 mutations resulting in an odd number of cysteine
residues are known to be associated with CADASIL. These
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mutations all occur in exons 2–24 of NOTCH3 that encode
34 epidermal growth factor (EGF)-like repeats in the extra-
cellular domain of the NOTCH3 protein. The large number
of exons combined with their high GC content makes com-
prehensive sequencing of this gene with traditional Sanger
sequencing (SS) expensive and time consuming. With the
advent of next-generation sequencing (NGS), the sequen-
cing of target genes, regions, exomes or whole genomes,
provides cost-effective, high-throughput screening suitable
for molecular diagnostics enabling detection of a wide array
of mutations with sensitivity and specificity. Here, we have
performed targeted gene sequencing using a custom five-
gene NGS panel [7], encompassing the coding sequences,
20–100 bp exon/intron boundaries and the 5′ and 3′UTR
regions of NOTCH3 in 44 patients.
Results
NGS-panel sequencing output
The sequencing output data from the Ion Torrent PGM
was analysed using the Ion Torrent platform-specific
software Torrent Suite V3.6 (Thermo Fisher Scientific,
Scoresby, Victoria, Australia). The 44 samples were se-
quenced using seven different Ion 316 chips, to generate
an average sequencing of 3,303,300 total reads, 477.4 Mb
total bases sequenced, and 472.2 Mb with 99 % of bases
aligned to the human complete genome (hg19) per Ion 316
chip. For all samples sequenced, the average read depth
across the target region was 560.65×, while the average
percentage of target bases covered at 20× or greater was 96
% and the average uniformity of coverage was 90.64 %.
Sequencing data analysis
Comprehensive screening for NOTCH3 using the Ampli-
Seq Custom NGS panel [7] (Thermo Fisher Scientific,
Scoresby, Victoria, Australia) for targeted gene sequencing
was conducted on 44 patients, previously screened for
standard sequencing exons (3 and 4) and/or (2,11, 18 and
19) by SS and classified as being negative for known
mutations.
Initial analysis using the IonReporter software
(Thermo Fisher Scientific, Scoresby, Victoria, Australia)
identified 42 variants scattered over NOTCH3 among
the 44 patients. An overview of all variants detected in
our study is shown in Additional file 1: Table S1 online.
Of these, nine particularly notable genetic variants were
identified in 10 patients (22.7 %) out of the 44 subjects:
five novel potential mutations (NOTCH3:NM_000435:ex-
on4:c.416A>T:p.D139V, exon1 1:c.1791C>G:p.C597W
and c.1820G>A: p.R607H, exon18: c.2929T>G,:
p.C977G; and exon20: c.3317A>G: p.Y1106C); three
previously reported disease-causing missense mutations
(NOTCH3:NM_000435:exon4:c.547T>Cp.C183R [8], exon
6:c.994C>T, p.R332C [9, 10]; and exon9: c.1394A>G:
p.Y465R [11]) and one novel synonymous genetic variant
in NOTCH3:NM_000435:exon16:c.2439G>A: p.E813E
[Tables 1 and 2]. Clinical information for all samples
was not available [see Additional file 2: Table S2]; how-
ever, the following clinical parameters were attributed
to the relevant samples in our cohort: (i) white matter
abnormalities were seen in patients with E813E, C183R
and R332C mutations; (ii) positive skin biopsy signs
were reported in patients with C977G, Y1106C, Y465C
and C183R and (iii) a family history of dementia and/or
stroke was reported in patients with E813E, C977G,
Y1106C, C183R, R332C and R465C mutations.
Molecular genetic testing using the custom NGS panel
encompassing five genes (NOTCH3, CACNA1A, ATP1A2,
SCN1A and TRESK genes) identified two remarkable vari-
ants in case C-36 (CACNA1A:NM_023035:c.832G>T:-
p.A278S and SCN1A:NM_006920:c.3924A>T: p.E1308D
[Table 1]). These mutations correspond to highly con-
served amino acid residues according to four in silico pre-
diction tools (PhyloP of score of >2.0, PolyPhen2 HVar of
score >0.7, and MutationTaster with a damaging effect and
GERP++ score above 5).
In addition to these variants, nine rare single nucleotide
polymorphisms (SNPs) in the NOTCH3 gene with minor
allele frequency (MAF) ≤0.1 % were observed in nine pa-
tients with no other causative mutation found in NOTCH3
[Additional file 1: Table S1 online and Table 3]. One pa-
tient (case C-3) was shown to carry two rare amino acid
changing variants p.S497L and p.A1020P in exons 9 and
19 of NOTCH3, respectively. All nine SNPs were further
assessed by seven in silico prediction programmes with
three of these variants (p.S497L, p.P496L and p.Y220Y)
shown to have a damaging effect by MutationTaster.
All variants detected by NGS and reported in this
study were visually confirmed using Integrative Genom-
ics Viewer (IGV v2.3) software [12] and compared with
NCBI reference sequences [13]. In order to verify the ac-
curacy of potential novel mutations identified by NGS,
SS was performed for all samples with the five non-
synonymous variants along with the synonymous new
variant showing complete consistency (100 %) between
the two methods [Fig. 1].
Analyses of the potential functional significance of the
six novel NOTCH3 genetic variants identified the
C597W, C977G and Y1106C missense mutations to be
pathogenic by six of the seven genetic prediction soft-
ware programmes (PhyloP, SIFT, PolyPhen2, Mutation-
Taster, AGVGD and PhD-SNP) [Table 1].
Finally, we compared the potential functional signifi-
cance of the three known pathogenic missense muta-
tions (C183R, R332C and Y465C) with the six novel
genomic variants identified using the same seven in
silico software programmes. The C183R and R332C mu-
tations showed a high potential damaging effect when
analysed by all seven programmes used; in contrast, the
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Table 1 Variants of unknown significance of NOTCH3, CACNA1A and SCN1A genes identified in eight suspicious CADASIL patients. RefSeq NM_000435, NM_001127221 and
NM_001165963
Sample ID Gene Gender Age Exon EGF-repeat Codon change (FWD) Protein change PhyloP SIFT PolyPhen2 HVar MutationTaster GERP++ AGVGD PhD-SNP
C-11 NOTCH3 F 42 4 3 c.416A>T p.Asp139Val C (1.89) T (0.06) P (0.499) D 5.02 C65 Non-neutral
C-4 NOTCH3 M 67 11 15 c.1791C>G p.Cys597Trp N (0.434) D (0) D (1.0) D 2.25 C65 Non-neutral
C-15 NOTCH3 F 52 11 15 c.1820G>A p.Arg607His C (2.21) T (0.54) B (0.0.026) D 3.22 C25 Neutral
C-24 NOTCH3 M 54 16 21 c.2439G>A p.Glu813Glu – – – D (splice site changes) – – –
C-10 and C-44 NOTCH3 F 74, 52 18 25 c.2929T>G p.Cys977Gly C (2.04) D (0) D (1.0) D 5.36 C65 Non-neutral
C-6 NOTCH3 F 51 20 28 c.3317A>G p.Tyr1106Cys C (1.92) D (0) D (0.998) D 5.08 C65 Non-neutral
C-36 CACNA1A M 60 6 – c.832G>T p.Ala278Ser C (2.46) T (0.13) D (0.963) D 5.27 NA Neutral
C-36 SCN1A M 60 20 – c.3924A>T p.Glu1308Asp C (2.08) T (0.37) P (0.727) D 5.46 NA Neutral
PhyloP, SIFT, Polyphen-2, MutationTaster, GERP++, AGVGD and PhD-SNP are functional prediction scores in which increasing values indicate a more damaging effect except SIFT score <0.05 has damaging effect
Abbreviations: C conserved, N not-conserved or neutral, D damaging or deleterious, P possible damaging, T tolerated, B benign, NA not applicable
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Table 2 Variants of known NOTCH3 mutations identified in three patients by NGS. RefSeq NM_000435.2
Sample ID Gender Age Exon EGF-repeat Codon change Protein change PhyloP SIFT PolyPhen2 HVar MutationTaster GERP++ AGVGD PhD-SNP Snp138
C-20 F 54 4 4 c.547T>C p.Cys183Arg C (1.82) D (0) D (1) D 4.32 C65 Non-neutral
C-42 F 47 6 8 c.994C>T p.Arg332Cys C (2.46) D (0.03) D (1) D 4.6 C65 Non-neutral rs137852641
C-14 M 33 9 11 c.1394A>G p.Tyr465Cys N (−0.833) T (0.08) P (0.886) D −4.41 C65 Non-neutral
PhyloP, SIFT, Polyphen-2, MutationTaster, GERP++, AGVGD and PhD-SNP are functional prediction scores in which increasing values indicate a more damaging effect except SIFT score <0.05 has damaging effect
Abbreviations: C conserved, N not-conserved or neutral, D damaging or deleterious, P possible damaging, T tolerated
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Table 3 Rare variants identified by NGS in the NOTCH3 gene. RefSeq NM_000435.2
Patient ID Locus. Ref Location Codon change Protein change PhyloP SIFT PolyPhen LRT MutationTaster GERP++ AGVGD PhD-SNP dbSNP MAF
C31 chr19:15281342 T Ex27 c.4914A>G WT (p.Glu1638Glu) 0.25 Poly rs149222385 0.001
C13, C28, C33 chr19:15290236 G Ex21 c.3399C>A p.His1133Gln −2.55 D P (0.68) NA Poly −8.6 C15 Neutral rs112197217 0.005
C3, C12 chr19:15291576 C Ex19 c.3058G>C p.Ala1020Pro 0.57 T (0.19) B (0.054) N (0.006) Poly 1.44 C25 Neutral rs35769976 0.083
C3 chr19:15296513 C In12 0.5 Poly rs147014533 0.006
C3 chr19:15299048 G Ex9 c.1490C>T p.Ser497Leu 2.35 T (0.33) B (0.036) N (0.018) D 5.04 C65 Neutral rs114207045 0.006
C34 chr19:15299051 G Ex9 c.1487C>T p.Pro496Leu 2.35 T (0.1) p (0.883) N (0.007) D 5.04 C65 Disease rs11670799 0.005
C9 chr19:15302790 G Ex4 c.660C>T WT (p.Tyr220Tyr) −1.85 D rs114457076 0.001
C3 chr19:15308287 G In2 −0.16 Poly rs188132716 0.006
C16 chr19:15308288 G In2 −0.98 Poly rs202151374 0.003
PhyloP, SIFT, Polyphen-2, Mutation Taster, GERP++, AGVGD, and PhD-SNP are functional prediction scores in which increasing values indicate a more damaging effect except SIFT score <0.05 has damaging effect
Abbreviations: B benign, C conserved, D damaging or deleterious, Ex exon, In intron, NA not applicable, N not-conserved or neutral, P possible damaging, Poly polymorphic, T tolerated, WT wild type
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Y465C mutation showed a tolerated or benign effect in
four of the seven in silico programmes [Table 2].
Discussion
Molecular genetic testing is an essential tool for accurate
CADASIL diagnosis. Several diagnostic approaches have
been used for CADASIL, in particular the use of skin bi-
opsy to detect unusual NOTCH3 expression. However,
despite the widespread use of biopsy testing, the low
sensitivity of this method in CADASIL diagnosis has
been reported [14]. In addition, previous work by
Markus et al. tested the sensitivity of single strand
(A) (B)
(C) (D)
(E) (F)
Fig. 1 Sequences (reverse complement) of the six novel genetic variants in NOTCH3 identified by NGS. The figure shows the six heterozygous
exonic point variants: a p.D139V in exon 4, b p.C597W in exon 11, c p.R607H in exon 11, d synonymous variant p.E813E in exon 16, e p.C977G in
exon 18 and f p.Y1106C in exon 20 identified in this study. Only bases non-concordant with consensus sequence are displayed in the target reads
with the integrative genomics viewer IGV [12]. The normal nucleotide and protein sequences are depicted at the bottom and top of the figure
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conformation polymorphism (SSCP) analysis for detect-
ing NOTCH3 mutations, with an effective success rate of
80 to 85 % [14]. More recently, He et al. reported that
varying and population-dependant results in the effect-
iveness of using the pre-genetic “CADASIL scale”
screening tool which evaluates clinical presentations and
neuroimaging data in an effort to minimise NOTCH3
gene testing [15, 16]. As such, current diagnosis relies
on the screening of all exons by sequencing to identify
mutations in NOTCH3.
We have previously demonstrated the efficiency of our
NGS panel for detecting known and novel mutations in a
cohort of episodic ataxia patients and increasing the rate
of mutation detection by 48 % [7]. We have now utilised
this custom targeted massively parallel NGS panel to
examine the coding sequences, intron/exon boundaries
including 20–100 bases of flanking intronic nucleotides
and the 5′ and 3′UTR regions of NOTCH3 in a cohort of
44 patients with clinically suspicious CADASIL.
Targeted gene sequencing analysis efficiently identified
nine novel genetic variants in NOTCH3, of which five non-
synonymous mutations (p.D139V, p.C597W, p.R607H,
p.C977G and p.Y1106C) and one synonymous variant
(p.E813E) have not been previously described. In addition,
three missense mutations previously reported as patho-
genic (C183R [8], R332C [9, 10] and Y465C [11]) but not
previously identified in our diagnostics cohort were also
detected [17]. In total, six typical CADASIL mutations in-
volving cysteine alterations were identified in seven pa-
tients (15.9 %) out of 44 subjects, a detection rate higher
than previously reported by Fernandez et al. and Bianchi et
al. [18, 19].
Interestingly, previous studies have revealed differ-
ences in the spectrum of NOTCH3 mutations between
Asian and Italian populations and populations of Cauca-
sian ethnicity [18, 20, 21]. Our results also showed no
evidence of strong clustering of NOTCH3 mutations in
specific exons. The variants identified in this study occur
in seven different exons (4, 6, 9, 11, 16, 18 and 20)
within the EGF-like repeat regions of the gene. The pa-
tient cohort encompasses different ethnic backgrounds,
reflecting the diversity of the Australian population. This
highlights the potential confounding factor in nations of
multiple ethnic backgrounds, where mutations may
occur at multiple sites making molecular diagnosis
difficult and time consuming if using traditional SS
methodologies. While exonic clustering in ethnic
groups is likely due to founder effects, de novo muta-
tions resulting in mutations in ethnically homogenous
populations are possible. In this instance, the use of
SS may still miss mutations in a proportion of pa-
tients suggesting that screening of all coding regions
in NOTCH3 is of benefit for the comprehensive mo-
lecular diagnosis of CADASIL.
Six of the missense mutations identified were stereo-
typical CADASIL mutations, resulting in a loss or gain
of one of the six cysteine residues (4, 8, 11, 15, 25 and
28) of the EGF-like repeats located in the extracellular
domain of NOTCH3 [4]. Any mutation within the cyst-
eine residues (a gain or loss) leads to an odd number of
cysteine residues and result in impaired dimerisation of
NOTCH3 or formation of inappropriate disulphide
bonds causing aberrant NOTCH3 signaling [22, 23]. As
such, these three mutations (p.C597W, p.C977G and
p.Y1106C) were considered to be disease-causing and
associated with the pure and typical pathogenetic mech-
anisms of CADASIL [4, 24]. The substitution of the
p.C597S has been previously identified in an Arabic fam-
ily [25], while the substitution of p.C977S has been re-
ported in a Chinese patient [26] with both mutations
found to be associated with CADASIL pathogenesis.
We also observed two novel amino acid substitutions
(p.D139V and p.R607H) not directly involving cysteine
residues, predicted to be possibly damaging and benign,
respectively. As discussed by Roy et al. [17], there is
some controversy over the classification non-cysteine
residue altering variants and their significance to CADA-
SIL. Several NOTCH3 alterations that do not affect cyst-
eine residues have been reported in families with
CADASIL, which may involve other disruptions to pro-
tein function, though these may result in changes that
effectively change cysteine residue availability [27–32]. It
is worth noting that the predicted score for p.D139V by
the SIFT programme (0.06) was more deleterious than
the known pathogenic mutation p.Y465C, with a score
of 0.08, technically considered to be benign. A SIFT
score from 0 to 0.05 indicates that the amino acid
change has a damaging effect. Further investigation of
this mutation is warranted to determine the effect of
these non-cysteine affecting changes on NOTCH3 func-
tion as well as on mediating signal transduction for vas-
cular development and inducing the pathology of
CADASIL. This provides new insights into the diagnosis
of and pathomechanisms causing CADASIL.
The last novel synonymous variant we identified
(p.E813E) was predicted by the MutationTaster programme
to cause the gain of an RNA splicing donor site. This gain
may result in altered protein function and therefore, despite
being silent, this variant could be a real mutation causing
CADASIL. Direct functional evaluation of NOTCH3 in this
patient is needed to confirm this hypothesis, but such stud-
ies were not able to be performed at this time.
The in silico analysis tools to analyse the detected vari-
ants also revealed some interesting potential ramifica-
tions of the previously identified p.Y465C mutation. In
2003, Razvi et al. described this amino acid substitution
as a mutation causing CADASIL [11]. In contrast, dur-
ing our analysis, the computational tools predicted this
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amino acid change as tolerated or benign. The PhyloP
score of 0.0272 and SIFT score of 0.08 (damaging score
<0.05) suggest this amino acid is not conserved. The
mutation is a classical CADASIL mutation; however, as
stated by Joutel et al. “mutations can be unambiguously
classified as pathogenic when they lead to an uneven
number of cysteine residues in one of the 34 EGFR
domains constituting the extracellular domain of the
receptor” [24]. This discrepancy between evolutionary
conservation and functional correlation models suggests
caution when using functional prediction software in
assigning a role to missense mutations involving cysteine
residues in NOTCH3. The in vivo effect of amino acid
substitutions should be the final arbiter for precisely de-
scribing their role in causing CADASIL, but as such
tests are laborious to undertake, they are rarely per-
formed for diagnoses. Careful consideration of the symp-
tomatic profile may be useful in such cases and in the
future when sufficient mutation data has accumulated
offering clinicians more precision in ascribing the func-
tional role of mutations in CADASIL.
Interestingly, in this study, patient C-36 demonstrated
compound heterozygosity for two missense mutations in
the CACNA1A and SCN1A genes (not normal target
genes for CADASIL screening) [Table 1]. Mutations
within these two ion channel genes are associated with
various autosomal dominant disorders: hemiplegic mi-
graine, episodic ataxia type 2, spinocerebellar ataxia
type 6 and epilepsy with previously reported overlap-
ping symptoms among these disorders [33–35]. It is
worth noting that the p.E1297D mutation in SCN1A
gene was previously reported in an Italian family with
idiopathic childhood epilepsy [36]. The linkage be-
tween CACNA1A and SCN1A gene mutations and
CADASIL has not previously been reported; therefore,
an ongoing study in our lab will investigate the effect
of these two variants/genes on CADASIL disease
pathophysiology.
In terms of the clinical classification of the detected
genetic variants, the full available evidence needs to be
considered. Typical CADASIL mutations involve the
addition or elimination of a cysteine residue in one of
the 34 NOTCH3 gene epidermal growth factor (EGF)-
like repeats, resulting in mismatched disulphide bridging
and altered protein function, a hypothesis which has
been borne out by observational and functional studies
[37, 38]. Under the current American College of Medical
Genetics and Genomics (ACMG) guidelines for variant
classification, functional studies supporting a damaging
effect for a variant on gene function constitute strong
evidence for pathogenicity. Each of the cysteine altering
variants also has multiple moderate and supporting lines
of evidence. These include presence in a disease-
associated functional domain; presence at a loci where
another pathogenic mutation is known (as determined
by searching HGMD, LOVD and VEP databases); ab-
sence from controls in population databases (1000 Ge-
nomes, dbSNP, ExAC); being the kind of variant
(missense SNV) associated with the disease; presence in
an individual with a clear phenotype; cosegregation with
disease in family members (only for patients C-10 and
C-44) and multiple in silico analyses predicting patho-
genicity. This combination of evidence is sufficient to
characterise them as pathogenic or disease-causing mu-
tations according to the ACMG guidelines [39].
For the non-cysteine altering NOTCH3 variants, there
is less information available. Family segregation analysis
and clinical information were not available for patients
C-11 (p.D39V) or C-15 (p. R607H). Despite being novel
amino acid changing variants in loci where disease-
causing mutations are known to exist and/or functional
domains, there is insufficient strength of evidence to
classify either variant as pathogenic or likely pathogenic.
Additionally, both these patients had complex pheno-
types that do not precisely map to CADASIL, and share
features of episodic ataxia or familial hemiplegic mi-
graine, indicating a potential overlapping pathophysi-
ology or comorbidities with these disorders. Thus, these
variants should be classified as variants of uncertain sig-
nificance (VOUS) according to the ACMG guidelines.
Patient C-24 with the synonymous variant (p.E318E) had
family history indicative of CADASIL, but no other sup-
porting evidence, though neither does the variant have
any criteria for being classified as benign. This variant
has also been classified as a VOUS.
Patient C-36, who bears variants in both CACNA1A
and SCN1A also, had no family members available for
further investigation. Neither variant has sufficient evi-
dence to indicate direct pathogenicity, despite being in
regions of these genes known to harbour disease-causing
mutations. Additionally, their presence in a gene which
causes symptoms overlapping with CADASIL indicates a
possible complex pathophysiology that requires more re-
search. Hence, these variants have been classified as
VOUS [39].
Finally, nine rare variants were identified in nine pa-
tients with no other causative mutation in NOTCH3
[Table 3]. Of these, three amino acid changing variants
(p.S497L, p.A1020P and p.H1133Q) were recently re-
ported by Abramycheva et al. [15] as normal polymor-
phisms in Russian CADASIL patients. However, in this
study, patient C-3 was found to carry non-cysteine
NOTCH3 gene variants (p.S496L and p.A1020P). As yet,
a comparison of the effect of these two non-cysteine var-
iants on the pathogenic mechanisms of CADASIL or
CADASIL-like phenotype [16] to a single non-cysteine
variant on disease pathogenesis has not been function-
ally tested.
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We have identified classical CADASIL-causing muta-
tions as well as a number of amino acid changing vari-
ants that have uncertain causative effects on this disease.
The study of a larger population cohort of cases includ-
ing symptomatic detail will likely provide more clinical
and molecular information about their impact as well as
the potential effect of any rare SNPs. Most interestingly,
our results indicate that there may be other CADASIL
gene/genes yet to be identified for inclusion in future
diagnostic arrays.
Conclusions
NGS technologies provide an effective method for
CADASIL and related disease diagnosis. Sequencing
large but targeted regions of interest of pooled DNA
from multiple samples is a promising tool for the discov-
ery of both known and novel variants associated with
disease. Compared with traditional SS, the NGS platform
provides increased accuracy along with reduced time
and assay costs necessary to perform routine genetic
diagnosis of CADASIL in ethnically heterogeneous pop-
ulations, putting such testing within reach of more
patients.
Materials and methods
Patients
Forty-four patients with a suspected clinical diagnosis of
CADASIL were re-screened using the NGS approach.
Patients referred to the Genomics Research Centre
(GRC) diagnostic laboratory for CADASIL molecular
testing through neurologists from Australia and New
Zealand and showed no mutations when using SS in our
standard exon sequencing (3 and 4) at the first stage and
(2, 11, 18 and 19) second stage [17]. Re-sequencing of
the 44 patients was based on the clinical information
had provided (i.e. positive skin biopsy results for CADA-
SIL or white matter changes in their MRI) indicating
that CADASIL-causing mutations may be present.
Molecular analysis
Ion AmpliSeq custom panel design
The AmpliSeq design target used in this report com-
prised the coding exons, exon/intron junctions and UTR
regions of the NOTCH3 gene. The Ampliseq automated
primer design tool (http://www.ampliseq.com) was used
to design primers covering 92.79 % of the desired target
area (8071 bp) aligned to the reference human genome
(hg 19). The missing regions include a 175 bp region in
exon 1 (position 15311617-15311792 on chromosome
19) and a 407 bp region in exon 24 (position 15288427-
15288834 on chromosome 19). The remainder of the 33
exons in the NOTCH3 gene were included at 100 %
coverage.
Library preparation
Genomic DNA was previously purified from peripheral
blood samples using standard extraction conditions
using Qiagen QIAamp DNA Blood Midi Kits as recom-
mended by the manufacturer. The Qubit dsDNA High
Sensitivity (HS) Assay Kit (Thermo Fisher Scientific,
Scoresby, Victoria, Australia) was used to ensure accur-
acy of DNA concentration input (10 ng/μL) to NGS li-
brary construction.
Library preparation was performed using the Ion Ampli-
Seq library kit 2.0 (Thermo Fisher Scientific, Scoresby,
Victoria, Australia) according to the standard protocol (Cat.
no. 4480441, Rev. 4.0). Briefly, for the multiplex PCR ampli-
fication, 10 ng of each genomic DNA sample was amplified
using the optimised modification method generated in our
laboratory allowing each primer pool to be amplified as a
5-μL reaction, rather than a 20-μL reaction (protocol is
available upon request). This was performed using 1 μL of
5× Ion AmpliSeq HiFi Master Mix, 2.5 μL of 2× AmpliSeq
Custom primer pool, 0.5 μL nuclease-free water and 1 μL
(10 ng/μL) of DNA. The reaction mix was heated for 2 min
at 99 °C for enzyme activation, followed by 18 two-step cy-
cles of 99 °C for 15 s and 60 °C for 4 min, ending with a
holding period at 10 °C.
After cycling, the two 5 μL/reaction pools for each sam-
ple were combined into a single well with a total volume
10 μL. The pooled amplified samples were partially
digested using 1 μL FuPa enzyme per sample at 50 °C for
10 min and 55 °C for 10 min followed by enzyme inactiva-
tion at 60 °C for 20 min. To enable multiple sample librar-
ies to be loaded per chip, 2 μL of a unique diluted
Barcode Adapter mix including Ion Xpress Barcode (num-
bered 1-16) and Ion P1 Adaptor at standard volumes was
ligated to the end of the digested amplicons using 1 μL
DNA ligase for 30 min at 22 °C followed by ligase inactiva-
tion for 10 min at 72 °C. The resulting unamplified
adaptor-ligated libraries were purified using the 22.5 μL
Agencourt AMPure XP system (Beckman Coulter, Brea,
CA, USA) followed by addition of 75 μL freshly prepared
70 % ethanol to each library.
After purification, the amplicon libraries were further
amplified to enrich material for accurate quantification
using 25 μL Platinum PCR SuperMix High Fidelity and
1 μL of library Amplification Primer Mix (Ion AmpliSeq
library kit 2.0, Thermo Fisher Scientific, Scoresby,
Victoria, Australia), at 98 °C for 2 min followed by five
two-step cycles of 98 °C for 15 s and 60 °C for 1 min.
The amplified amplicon libraries were then purified
using 12.5 μL Agencourt AMPure XP Reagent followed
by a second purification step with 30 μL AMPure XP
and 75 μL of freshly prepared 70 % ethanol added to
each library. The concentration and size of amplicons
was then determined using an Agilent BioAnalyzer DNA
High-Sensitivity chip (Agilent Technologies, Santa Clara,
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CA, USA), according to manufacturers’ instructions.
After quantification, each library was diluted to a con-
centration of ~10 pM prior to template preparation.
Subsequently, libraries (n = 16) were pooled in equimolar
amounts prior to further processing.
Template preparation (emulsion PCR) and sequencing
Emulsion PCR, emulsion breaking and enrichment (tem-
plate preparation) were performed using the Ion PGM
OT2 200 Template Kit (Thermo Fisher Scientific, Scoresby,
Victoria, Australia), according to the manufacturers’ in-
structions (part no. 4480974 Rev. 4.0).
After preparation of the ISPs, sequencing was per-
formed with an Ion Torrent Personal Genome Machine
(PGM) system using Ion Sequencing 200 Kit V2 and an
Ion 316 Chip (Thermo Fisher Scientific, Scoresby,
Victoria, Australia) according to the manufacturers’ pro-
cedures (Cat. no.4482006 Rev.1.0).
Bioinformatic analyses
The Ion Torrent PGM sequence data was mapped to the
complete human genome (hg19) by the Ion Torrent Suite
software and Torrent Server along with Torrent Mapping
Alignment Program optimised to Ion Torrent data. The
bam format file generated by Torrent Suite was uploaded
and visualised for human examination using Integrative
Genomics Viewer (IGV) 2.3 software [12]. The Ion Re-
porter software 4.0 (Thermo Fisher Scientific, Scoresby,
Victoria, Australia) was used to analyse data from Torrent
PGM. The software identifies variants and performs auto-
mated annotation on Ion PGM data. Variants were classi-
fied into simple categories, summarised into a report which
included links to appropriate databases for known variants.
DNA and protein sequences from NGS and SS were
compared with the NCBI reference sequences [13] and
the UCSC genome browser [40]. All rs ID numbers, lo-
cations, allele frequencies and genotypes for all variants
were determined based on SNPs reported in the dbSNP
database [41] and further analysed in the 1000 Genomes
data set. To predict the effect of non-synonymous single
nucleotide substitutions on protein structure, function
or phenotype, we used the wANNOVAR programme
[42, 43] which included the use of five functional predic-
tion software programmes for non-synonymous variants
(PhyloP [44], SIFT [45], PolyPhen2 [46], MutationTaster
[47] and GERP++ [48]). In silico prediction programmes
including AGVGD [49] and PhD-SNP [50] were also
used to predict causative variants. For synonymous vari-
ants and variants in non-coding regions, the Mutation-
Taster [47] software alone was used. All variants
detected were examined for associated information in
the public databases (at a minimum, dbSNP, OMIM,
LOVD, 1000 Genomes and HGMD) and in the pub-
lished literature.
Sanger sequencing (SS)
All detected novel mutations by NGS were further investi-
gated by SS. Molecular analysis of the NOTCH3 gene was
performed according to a previously described protocol
[17]. Briefly, genomic DNA was extracted using Qiagen
QIAamp DNA Blood Midi kits. DNA was amplified by
PCR to screen the exons containing novel mutations and
was performed with the primers shown in Additional file 3:
Table S3 online. PCR amplification for all exons were con-
ducted as previously described [17], and cycling protocols
is available for all exons upon request. PCR products were
purified using Affymetrix ExoSap-IT reagent (ExoSap-IT,
USB Corporation, Staufen, Germany) and directly se-
quenced for both sense and antisense strands using Big Dye
Terminator V3.1 (Applied Biosystems, Foster City,
CA, USA) on an ABI 3500 Genetic Analyser (Applied
Biosystems) according to established procedures.
Sequences were analysed with Chromas 2.33 software
(Technelysium, Brisbane, Queensland, Australia).
Additional files
Additional file 1: Table S1. Variants detected in NOTCH3 gene by NGS
in all 40 patients the transcript RefSeq NM_000435.2. (DOC 75 kb)
Additional file 2: Table S2. Overview of clinical data for patients tested
using the NGS panel with a clinical diagnosis of CADASIL. (DOC 59 kb)
Additional file 3: Table S3. List of primers used for PCR amplification
of exons with novel NOTCH3 mutations and variants detected by NGS.
(DOC 28 kb)
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